Last reviewed · How we verify
KADIAN
KADIAN, marketed by Actavis Inc., is an established therapeutic option in its class, with a key composition patent expiring in 2028. Its mechanism of action through specific receptor interactions provides a well-understood therapeutic profile, which is a significant strength. The primary risk is the potential increase in competition following the 2028 patent expiry.
At a glance
| Generic name | KADIAN |
|---|---|
| Also known as | Treatment B, Reference Product |
| Sponsor | Actavis Inc. |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
Common side effects
- Drowsiness
- Constipation
- Nausea
- Dizziness
- Anxiety
Serious adverse events
- Respiratory depression
- Respiratory arrest
- Apnea
- Circulatory depression
- Cardiac arrest
- Hypotension
- Shock
- Syncope
- Falls
Key clinical trials
- Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (PHASE3)
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (PHASE3)
- Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (PHASE3)
- Efficacy and Safety of Intravenous Lidocaine Versus Placebo in Patients Receiving Morphine-rachi Analgesia (PHASE3)
- Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. (PHASE3)
- An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis (PHASE1,PHASE2)
- Comparison of Intrathecal Morphine and Rectus Sheath Block for Postoperative Pain Management After Lower Abdominal Surgery With Midline Incision (NA)
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KADIAN CI brief — competitive landscape report
- KADIAN updates RSS · CI watch RSS
- Actavis Inc. portfolio CI